Replies to post #28766 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

They were looking for predictive factors in that retrospective, it was verified with observation, the latter is what the phase III trial relies upon to distinguish most, not all psPD, when they can't distinguish with the time given, 8-10 weeks post initial radiotherapy protocol, then they are either classified ePD or potentially ePD. The others are classified psPD and placed into the trial. The point is, that in your study, the scientists are looking for an indicator that tells them right off the bat (immediate end of first round of radiotherapy) which ones are psPD. That is not yet fully achievable.

[austinmediainc]

There are other papers, looking at others techniques, all generally being conducted now and to state that any one group has the magic ability to determine what is going on is false. Over time, yes, but not when early decisions need to be made.

I don't think anyone was stating that the company knew the prognosis when the patients entered the info arm, hence early or possible early progreesors. I am saying that the company should know that now, 2 years after the first patients entered and I believe they do know from Linda's comments about releasing the data. If they didn't she could have answered that the company doesn't know the breakout which would have been acceptable to me.